Risk stratification and anticoagulation strategies for post-PCI management in acute myocardial infarction patients with severe left ventricular dysfunction

https://doi.org/10.53730/ijhs.v7nS1.14249

Authors

  • Rahman Ullah MBBS, FCPS Cardiology, Specialist Cardiologist Health Department, KPK Pakistan
  • Imran Khawaja Internal Medicine, Ayub Teaching Hospital, Abbottabad, Pakistan
  • Rizwan Ullah Khan MBBS, FCPS Cardiology, Consultant Cardiologist, MTI/ Mardan Medical Complex, Mardan Pakistan
  • Laraib Murad Medical Officer, Cheema Heart Complex, Gujranwala Pakistan
  • Adnara Murad Medical Officer, Cheema Heart Complex, Gujranwala Pakistan
  • Wiqar Ahmad MBBS, FCPS (Medicine), Senior Registrar Medicine, Northwest Teaching Hospital, Peshawar, Pakistan

Keywords:

CHA2DS2-VASc score, embolus, HAS-BLED score, stroke, thrombotic events

Abstract

Background: Acute myocardial infarction (AMI) can result in severe left ventricular dysfunction (LVD) and cardiac failure, increasing risk of complications like stroke, thrombo-embolism, and recurrent AMI. Appropriate anticoagulation strategies are crucial for mitigating adverse events. The risk stratification of these patients involves evaluating their propensity for thrombotic and hemorrhagic events. Objectives: The study determined risk stratification and anticoagulation strategies for AMI patients with severe LVD post-PCI. Methods: At a tertiary hospital in Peshawar Pakistan, an investigation was conducted on 300 patients who presented with anterior AMI and 40% LVEF upon admission. Group A received anticoagulant therapy as part of their post-PCI management, whereas Group B received standard post-PCI management without anticoagulant therapy. Various risk scores, including CHA2DS2-VASc and HAS-BLED score, and major adverse cardiovascular events, were used in assessing patient's risk of thrombosis events of bleeding through risk stratification. Results: Mean age of patients was 63.47+8.19 years, mean BMI was 28.76+3.0 and 193/300 (64.33%) were females. Hypertension, hyperlipidemia and diabetes were the prevailing comorbidities (p<0.05) among the subjects. CHA2DS2-VASc scores classified patients into low-risk group (29.33%), medium risk (59.66%) and high-risk cohort (11%). 

Downloads

Download data is not yet available.

References

Jenča D, Melenovský V, Stehlik J, Staněk V, Kettner J, Kautzner J, Adámková V, Wohlfahrt P. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021 Feb;8(1):222-237.

Chahine J, Alvey H. Left Ventricular Failure. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2021.

Yang M, Guo F, Yang YJ, Jing ZC, Sun K. Prognostic Value of Preoperative Assessment of Left Ventricular Function in Patients Undergoing Percutaneous Coronary Intervention. Rev Cardiovasc Med. 2023;24(3):80.

Kim M, Moon I, Bae S, Seo H, Jung IH. Prognostic value of preoperative left ventricular global longitudinal strain for predicting postoperative myocardial injury and mortality in patients undergoing major non-cardiac surgery (SOLOMON study). Int J Cardiol. 2023 May 1;378:151-158.

Fang HY, Fang YN, Chen YC, Sheu JJ, Lee WC. The Impact of Complete Revascularization in Symptomatic Severe Left Ventricular Dysfunction between Coronary Artery Bypass Graft and Percutaneous Coronary Intervention. Cardiol Res Pract. 2023 Feb 28;2023:9226722.

Anderson JL, Adams CD, Antman EM, Bridges CR, Califf RM, Casey DE, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non STElevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116: e148–304.

Gaudino M, Hameed I, Khan FM, Tam DY, Rahouma M, Yongle R, et al. Treatment strategies in ischaemic left ventricular dysfunction: a network meta-analysis. European J Cardiothoracic Surg. 2020;ezaa319.

Wallace TW, Berger JS, Wang A, Velazquez EJ, Brown DL. Impact of left ventricular dysfunction on hospital mortality among patients undergoing elective percutaneous coronary intervention. The American Journal of Cardiology. 2009;103:355–360.

Fanaroff AC, Rao SV. Antiplatelet Therapy in Percutaneous Coronary Intervention. Interv Cardiol Clin. 2016 Apr;5(2):221-237.

Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. Intern Med. 2020 Feb 1;59(3):311-321.

Vogel RF, Delewi R, Badimon L, Angiolillo DJ, Vlachojannis GJ. Current Status and Future Direction of Antithrombotic Therapy for Patients with STEMI Undergoing Primary PCI. Rev Cardiovasc Med. 2022;23(9):297.

Rodriguez F, Harrington RA. Management of Antithrombotic Therapy after Acute Coronary Syndromes. N Engl J Med. 2021 Feb 4;384(5):452-460.

Onwordi EN, Gamal A, Zaman A. Anticoagulant Therapy for Acute Coronary Syndromes. Interv Cardiol. 2018 May;13(2):87-92.

Shoeb M, Fang MC. Assessing bleeding risk in patients taking anticoagulants. J Thromb Thrombolysis. 2013 Apr;35(3):312-9.

Bruoha S, Yosefy C, Taha L, Dvir D, Shuvy M, Jubeh R, Carasso S, Glikson M, Asher E. Mechanical Circulatory Support Devices for the Treatment of Cardiogenic Shock Complicating Acute Myocardial Infarction-A Review. J Clin Med. 2022 Sep 5;11(17):5241.

Allender JE, Reed BN, Foster JL, Moretz JD, Oliphant CS, Jennings DL, DiDomenico RJ, Coons JC. Pharmacologic Considerations in the Management of Patients Receiving Left Ventricular Percutaneous Mechanical Circulatory Support. Pharmacotherapy. 2017 Oct;37(10):1272-1283.

Chen PF, Yi JL, Pei JY, Tang L, Fang ZF, Zhou SH, Hu XQ. Post-Procedural Anticoagulation After Primary Percutaneous Coronary Intervention for Anterior Acute Myocardial Infarction With Severe Left Ventricular Dysfunction. Circ J. 2020 Sep 25;84(10):1728-1733.

Kontny F, Dale J, Abildgaard U, Pedersen TR. Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: The Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol. 1997;30:962 – 969.

Shacham Y, Birati EY, Rogovski O, Cogan Y, Keren G, Roth A. Left ventricular thrombus formation and bleeding complications during continuous in-hospital anticoagulation for acute anterior myocardial infarction. Isr Med Assoc J. 2012;14:742 – 746.

Yan Y, Gong W, Ma C, Wang X, Smith SC Jr, Fonarow GC, Morgan L, Liu J, Vicaut E, Zhao D, Montalescot G, Nie S; CCC-ACS Investigators. Postprocedure Anticoagulation in Patients With Acute ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2022 Feb 14;15(3):251-263.

Gong W, Li A, Ai H, Shi H, Wang X, Nie S. Safety of early discharge after primary angioplasty in low-risk patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2018;25:807–815.

Larson EA, German DM, Shatzel J, DeLoughery TG. Anticoagulation in the cardiac patient: A concise review. Eur J Haematol. 2019 Jan;102(1):3-19.

Ozaki Y, Hara H, Onuma Y, et al. CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. Cardiovasc Interv and Ther. 2022; 37:1-34.

Published

15-05-2023

How to Cite

Ullah, R., Khawaja, I., Khan, R. U., Murad, L., Murad, A., & Ahmad, W. (2023). Risk stratification and anticoagulation strategies for post-PCI management in acute myocardial infarction patients with severe left ventricular dysfunction. International Journal of Health Sciences, 7(S1), 651–661. https://doi.org/10.53730/ijhs.v7nS1.14249

Issue

Section

Peer Review Articles